title: Effects of combined exposure to pyridostigmine bromide and shaker stress on acoustic startle response, pre-pulse inhibition and open field behavior in mice.
abstract: The present study investigated the effect of combined exposure of pyridostigmine bromide (PB) and chronic shaker stress on acoustic startle responses (ASR), pre-pulse inhibition (PPI) and open field behavior of adult C57BL/6J mice. PB (10 mg kg(-1) day(-1) for 7 days) or saline was administered subcutaneously using osmotic Alzet minipumps implanted under the skin on the back of the mice. At the same time, the mice were exposed to 7 days of intermittent shaker stress. They were tested for ASR (100 dB and 120 dB stimuli) and PPI (70 dB + 100 dB and 70 dB + 120 dB) in the acoustic startle monitor system. The mice were assessed during the shaker stress on days 2 and 7 and 7, 14, 21 and 28 days after discontinuation of treatment. Separate groups of mice were tested in the open field in 15 min sessions on days 1, 3 and 6 during shaker stress and PB treatment. Exposure of mice to PB resulted in an exaggerated ASR, reduced PPI and non-significant decrease in locomotor activity. These behavioral changes were apparent only during exposure to PB. Repeated shaker stress did not have any effect on sensorimotor functions or open field behavior of mice. There was no prolonged or delayed effect of PB and/or stress on individual behavioral variables. The study found C57BL/6J mice to be behaviorally sensitive to PB treatment.
authors.affiliation: Wright State University, Boonshoft School of Medicine, Department of Pharmacology and Toxicology, Dayton, OH 45435, USA. exfadubm@savba.sk
authors.forename: M
authors.initials: M
authors.lastname: Dubovicky
authors.forename: S
authors.initials: S
authors.lastname: Paton
authors.forename: M
authors.initials: M
authors.lastname: Morris
authors.forename: M
authors.initials: M
authors.lastname: Mach
authors.forename: J B
authors.initials: JB
authors.lastname: Lucot
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D005106:Exploratory Behavior / Q000187:drug effects*; D015918:Infusion Pumps, Implantable; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects; D009068:Movement / Q000187:drug effects; D009433:Neural Inhibition / Q000187:drug effects*; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D013216:Reflex, Startle / Q000187:drug effects*; D013314:Stress, Mechanical; D013997:Time Factors; D018675:Toxicity Tests / Q000379:methods
chemical_list: D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide